Sonde Health Adds M3 Checklist to Its Mental Fitness Platform

Sonde Health Adds M3 Checklist to Its Mental Fitness Platform




Sonde Health Adds M3 Checklist to Its Mental Fitness Platform

New feature integration enhances Sonde’s mental health monitoring capabilities with a clinically validated mental health assessment

BOSTON–(BUSINESS WIRE)–Sonde Health, a leading enterprise vocal biomarker company, today announced that it has integrated the M3 Checklist into its Mental Fitness application programming interface (API), giving Sonde customers’ users access to a multi-conditional assessment tool that measures symptoms for major depression, bipolar disorder, anxiety disorder, and post-traumatic stress disorder (PTSD).

Developed by M-3 Information, LLC (M3), the M3 Checklist is a nationally recognized, peer-reviewed, and clinically validated tool that uses a 27-question online survey to document and assess a patient’s potential risk for mood and anxiety symptoms. The checklist, currently available through LabCorp, creates a symptom profile that helps clinicians give patients more personalized treatment recommendations and monitor their progress.

By making the M3 Checklist available in addition to another optional feature, voice-to-text transcription for journaling, Sonde’s Mental Fitness API will now offer healthcare providers, insurance payors, and pharma companies worldwide a more comprehensive product that can encourage people to make good health decisions by leveraging industry-leading vocal biomarker technology.

“The COVID-19 pandemic sparked a 25% increase in the global prevalence of anxiety and depression, and right now, close to one billion people worldwide suffer from some type of mental illness. Individuals need access to solutions that help them take a proactive approach to their mental health,” said David Liu, CEO of Sonde Health. “Sonde’s Mental Fitness API is already a simple and affordable way to better understand and stay on top of one’s mental well-being. The addition of M3’s validated assessment enhances our product offering, further strengthening our patient monitoring capabilities.”

“M3 and Sonde are both committed to delivering personalized observations that let providers devise the best short- and long-term outcomes for their patients. This collaboration only bolsters that mission,” said Michael Byer, President/Co-founder of M3. “There has been no product on the market that offers an easy and validated mental health assessment alongside voice-activated monitoring technology – until now.”

Virtare Health, a remote patient monitoring company, is a client of M3 that’s focused on promoting mental health awareness for its members. “We could not be more excited for this partnership between Sonde and M3, who together will provide our members with world-class online mental health detection and monitoring capabilities,” said Franklin Moses, CEO at Virtare Health. “Using this tool will further our efforts to deliver improved care results.”

The M3 Checklist feature is available for use via Sonde Health’s Mental Fitness API.

About Sonde Health

Sonde Health has developed an enterprise vocal biomarker platform that enables any company to either license respiratory or mental fitness monitoring product or create a novel vocal biomarker product. Sonde scales data collection, feature development, model creation and clinical validation in collaboration with its partners and customers. Leveraging over 1 million voice samples from 80,000+ individuals, Sonde uses advanced audio signal processing and machine learning to sense and analyze subtle vocal changes due to changes in a person’s physiology to provide key insights into health and well-being.

www.sondehealth.com

About M-3 Information

M-3 Information, LLC (“M3”) grew out of a collaborative of National Institute of Mental Health (NIMH) alumni and other academic researchers, clinicians, information technology and businesspeople committed to reengineering the detection of mental health disease and streamlining its integration into Primary Care, the point of first contact for over 70 percent of all mood and anxiety disorder cases. The M3 team identified a need to develop a multi-condition screen to replace the existing depression-only and anxiety-only screens that addressed only one form of mental illness. To address these problems, the M3 team focused on a mental health screen that could measure outcomes based on question responses. Visit M3Information.com for more information.

Contacts

Davisha Davis

Gregory FCA, for Sonde Health

davisha@gregoryfca.com
(315) 708-6800